We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Regeneron Pharmaceuticals Inc | NASDAQ:REGN | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.88 | 1.19% | 1,094.99 | 1,056.35 | 1,100.00 | 1,100.08 | 1,079.0855 | 1,087.89 | 282,365 | 01:00:00 |
From Jul 2019 to Jul 2024
By Kimberly Chin
Regeneron Pharmaceuticals Inc. (REGN) posted a 53% profit in the third quarter as it made breakthroughs in several of its treatments.
The company reported net income of $594.7 million, or $5.17 a share, compared with $388.3 million, or $3.32 a share, a year earlier. Analysts polled by Refinitiv were expecting $4.44 a share.
On an adjusted basis, Regeneron posted earnings of $5.87 a share, topping the $5.13 a share expected by analysts.
Regeneron said revenue rose 11% to $1.66 billion, driven in part by 7% growth in sales of its Eylea chemotherapy treatment.
For the year, Regeneron lowered its expectations of sales from its Sanofi collaboration to a range of $430 million to $455 million, from $455 million to $485 million as previously targeted.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
November 06, 2018 07:27 ET (12:27 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Regeneron Pharmaceuticals Chart |
1 Month Regeneron Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
